ENDOless: Building Data Infra for Women's Health

According to the World Health Organisation, endometriosis affects roughly 190 million women worldwide. And yet, according to Endometriosis UK, it typically takes seven to twelve years from the first symptoms to actually get diagnosed. Research published in the journal Human Reproduction found that the condition costs women around $15,000 a year, and that 69% of women with endometriosis miss work every single month because of their symptoms. This isn’t a rare condition — what’s been missing is the data infrastructure to actually manage it properly.

That’s exactly what ENDOless is building. Founded in Paris in 2024 by Alexandra Mont, the company is developing an AI-powered platform that turns women’s scattered, day-to-day health experiences into structured, ongoing health data. The goal is simple: give women dealing with chronic gynaecological conditions the same kind of serious data support that most other major health conditions already have — and make that data available to the researchers, doctors, and employers who actually need it.

How It All Started

Mont spent 16 years trying to get diagnosed. By the time doctors finally confirmed she had endometriosis, the disease had already fused her bladder, uterus, and colon together. Before all this, Mont had spent over a decade working in digital strategy and product leadership at major companies. After her diagnosis, she left her corporate career behind to build the platform she wished she’d had all those years.

She brought on Andrei Kuzmin as Chief Technology Officer, who brings over a decade of experience leading engineering teams building secure, scalable AI platforms for global clients. Together, they zeroed in on the core problem: women with endometriosis deal with symptoms that shift constantly — pain that moves around, fatigue that builds up over time, and mood, sleep, and lifestyle factors that all intersect in ways a single doctor’s visit just can’t capture. Regular healthcare data collection only gives you a snapshot. Endometriosis really needs data tracked over months and years to reveal any meaningful patterns.

What ENDOless Actually Built

The platform offers AI-powered symptom tracking, predictions for flare-ups, and personalised health insights. Users can log things like pain levels, mood, lifestyle triggers, and symptom patterns on an ongoing basis. The AI then looks for patterns, predicts flare-up cycles, and generates structured reports that doctors can actually use. It also connects with wearable devices to make that long-term data even richer.

Privacy is built in from the start — ENDOless follows GDPR-by-design principles, meaning data is securely stored, anonymised, and only shared when users explicitly agree to it.

The platform launched in beta in late 2025, followed by a full public launch in 2026. Before building the product, the team had over 250 conversations with women actually living with chronic gynaecological conditions — and those conversations directly shaped both the clinical design and the overall user experience.

How the Business Works

ENDOless makes money in three main ways. First, there’s a freemium consumer app — premium access costs €4.99 a month — which helps drive user adoption and generate data. Second, there’s a business-to-business platform aimed at employers who want to support their employees’ wellbeing. And third, there’s a “Research-as-a-Service” model, where anonymised, research-grade data is licensed to pharmaceutical companies and academic researchers.

The real strategic value here is the data itself. Consumer subscriptions help build that data layer, while institutional partnerships help put it to use for research and clinical purposes. In May 2025, the company opened a seed funding round targeting €2 million to help scale up its data infrastructure and grow its business partnerships. Looking ahead, ENDOless plans to expand beyond endometriosis to support conditions like PCOS, PMS, chronic pelvic pain, and a wider range of gynaecological and autoimmune conditions over time.

Recognition So Far

ENDOless was recognised as one of the most impactful innovations at ChangeNOW 2025 in Paris, and the company also presented at Web Summit 2024 in Lisbon. France Digitale included ENDOless in its 2026 Mapping of French AI Startups, placing it among 1,114 companies putting AI at the centre of what they do. ENDOless was also selected for the HIIT Health Innovation Programme, which supports health innovation in France alongside AP-HP, one of the largest hospital systems in Europe.

Why This Actually Matters

Right now, pharmaceutical companies working on treatments for chronic gynaecological conditions don’t have access to continuous, real-world patient data — and the kind of research-grade, long-term data ENDOless is collecting simply doesn’t exist anywhere else at this scale.

Mont explained her reasoning simply in an interview with Renewable Matter: she spent years dealing with exhaustion, brain fog, and chronic pain that doctors dismissed and colleagues didn’t understand — until she finally left her corporate career to build a platform where women’s pain could actually be seen, measured, predicted, and believed. The data ENDOless collects only becomes more valuable the longer people use it. The platform itself is still early — but the infrastructure being built is meant to last.